Absence of transforming growth factor-beta type II receptor is associated with poorer prognosis in HER2-negative breast tumours

dc.contributorUniversidade Estadual Paulista (UNESP)
dc.creatorPaiva, C. E.
dc.creatorLinde, Sandra Aparecida Drigo
dc.creatorRosa, F. E.
dc.creatorNeto, F. A. Moraes
dc.creatorCaldeira, Jose R. F.
dc.creatorSoares, F. A.
dc.creatorDomingues, Maria Aparecida Custódio
dc.creatorRogatto, Silvia Regina
dc.date2014-05-20T13:38:50Z
dc.date2016-10-25T16:54:53Z
dc.date2014-05-20T13:38:50Z
dc.date2016-10-25T16:54:53Z
dc.date2010-04-01
dc.date.accessioned2017-04-05T20:36:04Z
dc.date.available2017-04-05T20:36:04Z
dc.identifierAnnals of Oncology. Oxford: Oxford Univ Press, v. 21, n. 4, p. 734-740, 2010.
dc.identifier0923-7534
dc.identifierhttp://hdl.handle.net/11449/13470
dc.identifierhttp://acervodigital.unesp.br/handle/11449/13470
dc.identifier10.1093/annonc/mdp518
dc.identifierWOS:000276045600009
dc.identifierhttp://dx.doi.org/10.1093/annonc/mdp518
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/860791
dc.descriptionBackground: The clinical relevance of transforming growth factor-beta (TGF-beta)-signalling pathway in breast carcinomas (BCs) remained elusive. This study aimed to evaluate the prognostic value of TGF-beta and transforming growth factor-beta type II receptor (TGF-beta RII) expression levels in tumour cells and their association with the established biomarkers in BC.Patients and methods: In 324 BC from patients with long-term follow-up, the TGF-beta 1 and TGF-beta RII transcript and protein expression levels were assessed.Results: TGF-beta 1 and TGF-beta RII down-expression was significantly associated with BC. Negative TGF-beta 1 and TGF-beta RII protein status was associated with the development of distant metastasis (P = 0.003 and P = 0.029, respectively). In multivariate analysis, TGF-beta 1-positive tumours were associated with increased disease-free survival (DFS) [hazard ratio (HR) = 0.489, P = 0.003]. TGF-beta RII positivity was an independent prognostic factor for DFS (HR = 0.439, P = 0.001) and overall survival (OS) (HR = 0.409, P = 0.003) in human epidermal growth factor receptor2 (HER2)-negative patients. Absence of TGF-beta 1 and TGF-beta RII proteins in breast tumour cells was significantly associated with metastasis development.Conclusions: To the best of our knowledge, this is the first report indicating the relevance of HER2 status in discriminating TGF-beta RII as a prognostic marker for DFS and OS in human BC. These data indicate that TGF-beta RII protein analysis in tumour cells could be introduced in clinical practice as additional prognostic biomarker in HER2-negative BC.
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.languageeng
dc.publisherOxford University Press
dc.relationAnnals of Oncology
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectbreast cancer
dc.subjectHER2
dc.subjectprognostic markers
dc.subjectTGF-beta 1
dc.subjectTGF-beta RII
dc.titleAbsence of transforming growth factor-beta type II receptor is associated with poorer prognosis in HER2-negative breast tumours
dc.typeOtro


Este ítem pertenece a la siguiente institución